{Reference Type}: Journal Article
{Title}: Rates of resistance to ceftazidime-avibactam and ceftolozane-tazobactam among patients treated for multidrug-resistant Pseudomonas aeruginosa bacteremia or pneumonia.
{Author}: Shah S;Kline EG;Haidar G;Squires KM;Pogue JM;McCreary EK;Ludwig J;Clarke LG;Stellfox M;Van Tyne D;Shields RK;
{Journal}: Clin Infect Dis
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jun 21
{Factor}: 20.999
{DOI}: 10.1093/cid/ciae332
{Abstract}: Among consecutive patients with multidrug-resistant Pseudomonas aeruginosa bacteremia or pneumonia we found those treated with ceftazidime-avibactam were more likely to develop resistance (defined as ≥4-fold increased MIC) than those treated with ceftolozane-tazobactam (40% vs. 10%; P=0.002). Ceftazidime-avibactam resistance was associated with new mutations in ampC and efflux regulatory pathways.